在根治性膀胱切除术四联复合终点中加入新辅助化疗
这项回顾性多中心分析纳入2002至2023年因膀胱癌行根治性膀胱切除术的患者590例,评估将新辅助化疗纳入四联复合终点形成五联评分的影响。233例(39.5%)达到全部四联终点,其中82例(13.9%) additionally接受新辅助化疗达到五联。四联终点与更好的肿瘤特异性生存和总生存显著相关,加入新辅助化疗后对肿瘤特异性生存和总生存的区分度进一步改善。作者据此提出新的五联评分,可能作为标准化结局报告和衡量根治性膀胱切除术质量的工具。
要点
- 590例根治性膀胱切除术患者中233例(39.5%)达到四联复合终点。
- 四联终点与更好的肿瘤特异性生存(HR 0.49)和总生存(HR 0.48)显著相关。
- 四联终点加新辅助化疗形成五联,对肿瘤特异性生存(HR 0.21)和总生存(HR 0.26)区分度更佳。
核心结论
- 作者提出新的五联评分,可能作为标准化结局报告和衡量根治性膀胱切除术质量的工具。
研究设计与样本
- 回顾性多中心分析,纳入2002至2023年因膀胱癌行根治性膀胱切除术、接受或不接受新辅助化疗的患者,共590例。
主要发现
- 233例(39.5%)患者达到全部四联复合终点,其中82例(13.9%) additionally接受新辅助化疗达到五联。
- 达到四联复合终点与更好的肿瘤特异性生存显著相关(HR 0.49,95%CI 0.32-0.75;P=0.001)。
- 达到四联复合终点与更好的总生存显著相关(HR 0.48,95%CI 0.34-0.69;P<0.01)。
- 四联复合终点加入新辅助化疗后,对肿瘤特异性生存的区分度显著改善(HR 0.21,95%CI 0.08-0.57;P=0.002)。
- 四联复合终点加入新辅助化疗后,对总生存的区分度显著改善(HR 0.26,95%CI 0.12-0.55;P<0.01)。
关键数值与推荐
- 四联复合终点包括:淋巴结清扫≥16枚、软组织手术切缘阴性、术后30天内无重大并发症、根治性膀胱切除术无延迟。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the impact of incorporating neoadjuvant chemotherapy (NAC) into the 'quadrifecta' outcomes composite for reporting outcomes of radical cystectomy (RC) creating a pentafecta score. PATIENTS AND METHODS: This is a retrospective multicentre analysis of patients treated with RC, with or without NAC, for bladder cancer between 2002 and 2023. The primary outcome was the effect of adding NAC to a quadrifecta outcomes composite on cancer-specific (CSS) and overall survival (OS). The quadrifecta outcomes composite included a yield of ≥16 lymph nodes, negative soft tissue surgical margin, absence of major complication within 30 days from surgery, and no delay in RC. RESULTS: A total of 590 patients were included in the analyses. A total of 233 (39.5%) patients achieved all quadrifecta outcomes and 82 (13.9%) patients were additionally treated with NAC, achieving the pentafecta. Achieving the quadrifecta outcomes composite was significantly associated with better CSS (hazard ratio [HR] 0.49, 95% confidence interval [CI] 0.32-0.75; P = 0.001) and OS (HR 0.48, 95% CI 0.34-0.69; P < 0.01). The addition of NAC to the quadrifecta composite outcomes significantly improved the discrimination of patients more likely to have better CSS (HR 0.21, 95% CI 0.08-0.57; P = 0.002) and OS (HR 0.26, 95% CI 0.12-0.55; P < 0.01). CONCLUSION: We propose a new pentafecta that may serve as a tool for standardising outcomes reporting and measuring the quality of RC.
引用
- D'Andrea D, Soria F, Moschini M, et al. Addition of neoadjuvant chemotherapy to a 'quadrifecta' composite in radical cystectomy. BJU Int. 2024. PMID: 38483124. doi:10.1111/bju.16331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。